R-Pharm to supply 48 million COVID medicine to hospitals in Bashkiria

The Moscow joint-stock company R-Pharm has received contracts for the supply of a drug based on the active ingredient favipiravir to 12 medical institutions in Bashkiria. The company became the only participant in the electronic auction and will supply medicines at the maximum price of 47.9 million rubles, follows from the information posted on the public procurement portal.

The organizer of the auction was the Republican Clinical Infectious Diseases Hospital (RCCH). The winner of the auction must deliver the drug, in addition to the “infectious disease” itself, to Belebeevskaya, Meleuzovskaya, Mesyagutovskaya, Chishminskaya, Tuymazinskaya central district hospitals, to city hospitals No. 5, No. 8, No. 10 and No. to the city hospital of Neftekamsk. Medicines will be paid at the expense of medical institutions.

In total, 400.1 thousand tablets in a dosage of 200 mg are purchased for these hospitals in the region. Most of them - 70.6 thousand - will be supplied for the needs of the RCCH, 100 thousand tablets will be purchased by the 18th Ufa hospital, 50 thousand - by the Demsky district covid hospital. Medical institutions in the districts order from 2 to 10 thousand tablets. The remaining shelf life of the drug must be at least eight months from the date of delivery.

As RBC reported, favipiravir was developed by the Japanese company Fujifilm Holdings Corp. as a remedy against new types of influenza. In the spring of 2020, it was tested in Japan for the ability to help patients with CORONAVIRUS, but the researchers decided that the drug was ineffective. At the same time, Chinese scientists said that it can be used to treat covid-19 , and experts from India made the same conclusion. In RUSSIA, the effectiveness of the domestic analogue of favipiravir was established in the course of three clinical trials, after which the drug was approved for the treatment of coronavirus. In July 2020, R-Pharm announced the registration of the Coronavirus drug based on favipiravir for the treatment of COVID-19.

R-Pharm is a Russian high-tech pharmaceutical company, one of the largest pharmaceutical companies in Russia. According to RBC Company data, the joint-stock company was registered on August 17, 2001 in Moscow. The founder is Alexei Repik, President of the Business Russia organization. Vasily Ignatiev is the General DIRECTOR. In 2020, the company's revenue amounted to 120.5 billion rubles, net profit - 17.9 billion.